Sio Gene Therapies Inc
NASDAQ:SIOX
Intrinsic Value
Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. [ Read More ]
The intrinsic value of one SIOX stock under the Base Case scenario is 0.623 USD. Compared to the current market price of 0.478 USD, Sio Gene Therapies Inc is Undervalued by 23%.
Valuation Backtest
Sio Gene Therapies Inc
Run backtest to discover the historical profit from buying and selling SIOX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Sio Gene Therapies Inc
Current Assets | 47.3m |
Cash & Short-Term Investments | 46.1m |
Receivables | 400k |
Other Current Assets | 800k |
Current Liabilities | 2.2m |
Accounts Payable | 200k |
Accrued Liabilities | 1.5m |
Other Current Liabilities | 500k |
Earnings Waterfall
Sio Gene Therapies Inc
Revenue
|
0
USD
|
Operating Expenses
|
-29.4m
USD
|
Operating Income
|
-29.4m
USD
|
Other Expenses
|
540k
USD
|
Net Income
|
-28.8m
USD
|
Free Cash Flow Analysis
Sio Gene Therapies Inc
What is Free Cash Flow?
SIOX Profitability Score
Profitability Due Diligence
Sio Gene Therapies Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Sio Gene Therapies Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
SIOX Solvency Score
Solvency Due Diligence
Sio Gene Therapies Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Sio Gene Therapies Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIOX Price Targets Summary
Sio Gene Therapies Inc
Ownership
SIOX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SIOX Price
Sio Gene Therapies Inc
Average Annual Return | -50.92% |
Standard Deviation of Annual Returns | 14.19% |
Max Drawdown | -100% |
Market Capitalization | 3.2m USD |
Shares Outstanding | 73 975 196 |
Percentage of Shares Shorted | 0.13% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2015-06-11. The firm is focused on developing gene therapies for neurodegenerative diseases. The firm is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The firm is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.
Contact
IPO
Employees
Officers
The intrinsic value of one SIOX stock under the Base Case scenario is 0.623 USD.
Compared to the current market price of 0.478 USD, Sio Gene Therapies Inc is Undervalued by 23%.